EPCAM and neoplasm: First, we assessed, by RNA-seq,40 the expression of PGLYRP1 in EPCAM+ cells from the Espinet et al dataset.40 Overall, there was an increase in PGLYRP1 expression in tumours compared with healthy adjacent tissue; however, many tumours expressed low levels of PGLYRP1 (figure 8A), as would be expected of a marker (ie, CSC marker) whose expression is restricted to a subpopulation of cells.